Repair of genome destabilizing lesions

Radiation Research

Volumn 164, Issue 4 I, 2005, Pages 345-356

  Reddy, Madhava C ^a   Vasquez, Karen M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARCINOGEN; CHLORMETHINE DERIVATIVE; CISPLATIN; CYCLINE; CYCLOBUTANE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA B; DOUBLE STRANDED DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; EXONUCLEASE; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; MELPHALAN; MITOMYCIN C; MUSTARD GAS DERIVATIVE; OXIDIZING AGENT; POLYCYCLIC AROMATIC HYDROCARBON; PSORALEN; REPLICATION FACTOR C; REPLICATION PROTEIN A; SINGLE STRANDED DNA; TRANSCRIPTION FACTOR IIH;

ATAXIA TELANGIECTASIA; BLOOM SYNDROME; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DEATH; COCKAYNE SYNDROME; COLORECTAL CANCER; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DNA METABOLISM; DNA MODIFICATION; DNA RECOMBINATION; DNA REPAIR; DNA SEQUENCE; DNA STRAND BREAKAGE; DNA STRUCTURE; DRUG CYTOTOXICITY; EXCISION REPAIR; FAMILIAL CANCER; FANCONI ANEMIA; GENE MUTATION; GENETIC DISORDER; GENOMIC INSTABILITY; HUMAN; INTERCALATION COMPLEX; IONIZING RADIATION; LIPID DEGRADATION; MAMMAL CELL; MISMATCH REPAIR; NIJMEGEN BREAKAGE SYNDROME; OXIDATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA INTERACTION; PUVA; REVIEW; ROTHMUND THOMSON SYNDROME; TRICHOTHIODYSTROPHY; TRIPLE HELIX; ULTRAVIOLET RADIATION; WERNER SYNDROME; XERODERMA PIGMENTOSUM;

ANIMALS; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DNA REPAIR; FICUSIN; GENOMIC INSTABILITY; HIGH MOBILITY GROUP PROTEINS; HUMANS; NEOPLASMS;

MAMMALIA;

EID: 25444501238     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3419.1     Document Type: Review

References (125)

1. A. Sancar, L. A. Lindsey-Boltz, K. Unsal-Kaccmaz and S. Linn, Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73, 39-85 (2004).
2. J. H. Hoeijmakers, Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
3. O. D. Scharer, Chemistry and biology of DNA repair. Angew. Chem. Int. Ed. Engl. 42, 2946-2974 (2003).
4. T. Lindahl, Instability and decay of the primary structure of DNA. Nature 362, 709-715 (1993).
5. C. Helene, Molecular mechanisms for the recognition of damaged DNA regions by peptides and proteins. Adv. Biophys. 20, 177-186 (1985).
6. L. A. Frederico, T. A. Kunkel and B. R. Shaw, A sensitive genetic assay for the detection of cytosine deamination: Determination of rate constants and the activation energy. Biochemistry 29, 2532-2537 (1990).
7. B. M. Sutherland, P. V. Bennett, O. Sidorkina and J. Laval, Clustered DNA damages induced in isolated DNA and in human cells by low doses of ionizing radiation. Proc. Natl. Acad. Sci. USA 97, 103-108 (2000).
8. A. P. Breen and J. A. Murphy, Reactions of oxyl radicals with DNA. Free. Radic. Biol. Med. 18, 1033-1077 (1995).
9. M. R. Lieber, Pathological and physiological double-strand breaks: Roles in cancer, aging, and the immune system. Am. J. Pathol. 153, 1323-1332 (1998).
10. K. Rothkamm and M. Lobrich, Misrepair of radiation-induced DNA double-strand breaks and its relevance for tumorigenesis and cancer treatment. Int. J. Oncol. 21, 433-440 (2002).
11. 1 arrest. Proc. Natl. Acad. Sci. USA 93, 4827-4832 (1996).
12. J. de Boer and J. H. Hoeijmakers, Nucleotide excision repair and human syndromes. Carcinogenesis 21, 453-460 (2000).
13. V. A. Bohr, DNA damage and its processing, relation to human disease. J. Inherit. Metab. Dis. 25, 215-222 (2002).
14. A. R. Lehmann, DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 85, 1101-1111 (2003).
15. R. D. Wood, Human diseases associated with defective DNA excision repair. J. R. Coll. Physicians Lond. 25, 300-303 (1991).
16. L. A. Loeb, K. R. Loeb and J. P. Anderson, Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA 100, 776-781 (2003).
17. M. J. Schofield and P. Hsieh, DNA mismatch repair: Molecular mechanisms and biological function. Annu. Rev. Microbiol. 57, 579-608 (2003).
18. B. D. Harfe and S. Jinks-Robertson, DNA mismatch repair and genetic instability. Annu. Rev. Genet. 34, 359-399 (2000).
19. P. Modrich and R. Lahue, Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 65, 101-133 (1996).
20. R. Fishel, M. K. Lescoe, M. R. Rao, N. G. Copeland, N. A. Jenkins, J. Garber, M. Kane and R. Kolodner, The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75, 1027-1038 (1993).
21. P. Peltomaki and H. F. Vasen, Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113, 1146-1158 (1997).
22. A. Fedier and D. Fink, Mutations in DNA mismatch repair genes: Implications for DNA damage signaling and drug sensitivity. Int. J. Oncol. 24, 1039-1047 (2004).
23. B. S. Thoma and K. M. Vasquez, Critical DNA damage recognition functions of XPC-hHR23B and XPA-RPA in nucleotide excision repair. Mol. Carcinog. 38, 1-13 (2003).
24. P. C. Hanawalt, Subpathways of nucleotide excision repair and their regulation. Oncogene 21, 8949-8956 (2002).
25. A. Aboussekhra, M. Biggerstaff, M. K. Shivji, J. A. Vilpo, V. Moncollin, V. N. Podust, M. Protic, U. Hubscher, J. M. Egly and R. D. Wood, Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 80, 859-868 (1995).
26. D. Mu, C. H. Park, T. Matsunaga, D. S. Hsu, J. T. Reardon and A. Sancar, Reconstitution of human DNA repair excision nuclease in a highly defined system. J. Biol. Chem. 270, 2415-2418 (1995).
27. M. L. Dronkert and R. Kanaar, Repair of DNA interstrand crosslinks. Mutat. Res. 486, 217-247 (2001).
28. L. H. Thompson and D. Schild, Recombinational DNA repair and human disease. Mutat. Res. 509, 49-78 (2002).
29. H. P. Spielmann, T. J. Dwyer, S. S. Sastry, J. E. Hearst and D. E. Wemmer, DNA structural reorganization upon conversion of a psoralen furan-side monoadduct to an interstrand cross-link: Implications for DNA repair. Proc. Natl. Acad. Sci. USA 92, 2345-2349 (1995).
30. W. L. Morison, Psoralen ultraviolet A therapy in 2004. Photodermatol. Photoimmunol. Photomed. 20, 315-320 (2004).
31. E. D. Baron and S. R. Stevens, Phototherapy for cutaneous T-cell lymphoma. Dermatol. Ther. 16, 303-310 (2003).
32. R. Johnson, L. Staiano-Coico, L. Austin, I. Cardinale, R. Nabeya-Tsukifuji and J. G. Krueger, PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem. Photobiol. 63, 566-571 (1996).
33. S. Q. Wang, R. Setlow, M. Berwick, D. Polsky, A. A. Marghoob, A. W. Kopf and R. S. Bart, Ultraviolet A and melanoma: A review. J. Am. Acad. Dermatol. 44, 837-846 (2001).
34. K. M. Vasquez and P. M. Glazer, Triplex-forming oligonucleotides: Principles and applications. Q. Rev. Biophys. 35, 89-107 (2002).
35. L. E. Xodo, S. Cogoi and V. Rapozzi, Anti-gene strategies to downregulate gene expression in mammalian cells. Curr. Pharm. Des. 10, 805-819 (2004).
36. K. M. Vasquez and J. H. Wilson, Triplex-directed modification of genes and gene activity. Trends Biochem. Sci. 23, 4-9 (1998).
37. K. M. Vasquez, L. Narayanan and P. M. Glazer, Specific mutations induced by triplex-forming oligonucleotides in mice. Science 290, 530-533 (2000).
38. K. M. Vasquez, K. Marburger, Z. Intody and J. H. Wilson, Manipulating the mammalian genome by homologous recombination. Proc. Natl. Acad. Sci. USA 98, 8403-8410 (2001).
39. C. Helene, N. T. Thuong and A. Harel-Bellan, Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy. Ann. NY Acad. Sci. 660, 27-36 (1992).
40. A. Majumdar, A. Khorlin, N. Dyatkina, F. L. Lin, J. Powell, J. Liu, Z. Fei, Y. Khripine, K. A. Watanabe and J. George, Targeted gene knockout mediated by triple helix forming oligonucleotides. Nat. Genet. 20, 212-214 (1998).
41. A. F. Faruqi, H. J. Datta, D. Carroll, M. M. Seidman and P. M. Glazer, Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway. Mol. Cell. Biol. 20, 990-1000 (2000).
42. A. F. Faruqi, M. M. Seidman, D. J. Segal, D. Carroll and P. M. Glazer, Recombination induced by triple-helix-targeted DNA damage in mammalian cells. Mol. Cell. Biol. 16, 6820-6828 (1996).
43. Z. Luo, M. A. Macris, A. F. Faruqi and P. M. Glazer, High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells. Proc. Natl. Acad. Sci. USA 97, 9003-9008 (2000).
44. G. Felsenfeld, D. R. Davies and A. Rich, Formation of a three-stranded polynucleotide molecule. J. Am. Chem. Soc. 79, 2023-2024 (1957).
45. P. B. Dervan, Design of sequence-specific DNA-binding molecules. Science 232, 464-471 (1986).
46. M. Faria, C. D. Wood, L. Perrouault, J. S. Nelson, A. Winter, M. R. White, C. Helene and C. Giovannangeli, Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. Proc. Natl. Acad. Sci. USA 97, 3862-3867 (2000).
47. M. Cooney, G. Czernuszewicz, E. H. Postel, S. J. Flint and M. E. Hogan, Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 241, 456-459 (1988).
48. E. H. Postel, S. J. Flint, D. J. Kessler and M. E. Hogan, Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc. Natl. Acad. Sci. USA 88, 8227-8231 (1991).
49. K. M. Vasquez, G. Wang, P. A. Havre and P. M. Glazer, Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res. 27, 1176-1181 (1999).
50. G. Wang, M. M. Seidman and P. M. Glazer, Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair. Science 271, 802-805 (1996).
51. F. X. Barre, S. Ait-Si-Ali, C. Giovannangeli, R. Luis, P. Robin, L. L. Pritchard, C. Helene and A. Harel-Bellan, Unambiguous demonstration of triple-helix-directed gene modification. Proc. Natl. Acad. Sci. USA 97, 3084-3088 (2000).
52. L. A. Christensen, C. J. Conti, S. M. Fischer and K. M. Vasquez, Mutation frequencies in murine keratinocytes as a function of carcinogenic status. Mol. Carcinog. 40, 122-133 (2004).
53. K. M. Vasquez, T. G. Wensel, M. E. Hogan and J. H. Wilson, High-efficiency triple-helix-mediated photo-cross-linking at a targeted site within a selectable mammalian gene. Biochemistry 35, 10712-10719 (1996).
54. A. L. Guieysse, D. Praseuth, M. Grigoriev, A. Harel-Bellan and C. Helene, Detection of covalent triplex within human cells. Nucleic-Acids Res. 24, 4210-4216 (1996).
55. 125I-labeled triplex-forming oligonucleotides conjugated with nuclear localization signal peptide. Antisense Nucleic Acid Drug Dev. 12, 43-49 (2002).
56. F. Nagatsugi, S. Sasaki, P. S. Miller and M. M. Seidman, Site-specific mutagenesis by triple helix-forming oligonucleotides containing a reactive nucleoside analog. Nucleic Acids Res. 31, e31 (2003).
57. H. J. Datta, P. P. Chan, K. M. Vasquez, R. C. Gupta and P. M. Glazer, Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J. Biol. Chem. 276, 18018-18023 (2001).
58. K. M. Vasquez, J. Christensen, L. Li, R. A. Finch and P. M. Glazer, Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions. Proc. Natl. Acad. Sci. USA 99, 5848-5853 (2002).
59. F. X. Barre, C. Giovannangeli, C. Helene and A. Harel-Bellan, Covalent crosslinks introduced via a triple helix-forming oligonucleotide coupled to psoralen are inefficiently repaired. Nucleic Acids Res. 27, 743-749 (1999).
60. F. Guillonneau, A. L. Guieysse, S. Nocentini, C. Giovannangeli and D. Praseuth, Psoralen interstrand cross-link repair is specifically altered by an adjacent triple-stranded structure. Nucleic Acids Res. 32, 1143-1153 (2004).
61. A. L. Guieysse, D. Praseuth, C. Giovannangeli, U. Asseline and C. Helene, Psoralen adducts induced by triplex-forming oligonucleotides are refractory to repair in HeLa cells. J. Mol. Biol. 296, 373-383 (2000).
62. M. C. Reddy, J. Christensen and K. M. Vasquez, Interplay between human high mobility group protein 1 and replication protein A on psoralen-cross-linked DNA. Biochemistry 44, 4188-4195 (2005).
63. P. B. Arimondo, S. Angenault, L. Halby, A. Boutorine, F. Schmidt, C. Monneret, T. Garestier, J. S. Sun, C. Bailly and C. Helene, Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin- oligonucleotide conjugates. Nucleic Acids Res. 31, 4031-4040 (2003).
64. I. G. Panyutin, T. A. Winters, L. E. Feinendegen and R. D. Neumann, Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Q. J. Nucl. Med. 44, 256-267 (2000).
65. T. L. Phillips, 50 years of radiation research: Medicine. Radiat. Res. 158, 389-417 (2002).
66. Y. Nishimura, Rationale for chemoradiotherapy. Int. J. Clin. Oncol. 9, 414-420 (2004).
67. R. S. Cole, Repair of DNA containing interstrand crosslinks in Escherichia coli: Sequential excision and recombination. Proc. Natl. Acad. Sci. USA 70, 1064-1068 (1973).
68. F. M. Sladek, M. M. Munn, W. D. Rupp and P. Howard-Flanders, In vitro repair of psoralen-DNA cross-links by RecA, UvrABC, and the 5′-exonuclease of DNA polymerase I. J. Biol. Chem. 264, 6755-6765 (1989).
69. R. S. Cole, D. Levitan and R. R. Sinden, Removal of psoralen interstrand cross-links from DNA of Escherichia coli: Mechanism and genetic control. J. Mol. Biol. 103, 39-59 (1976).
70. S. Cheng, A. Sancar and J. E. Hearst, RecA-dependent incision of psoralen-crosslinked DNA by (A)BC excinuclease. Nucleic Acids Res. 19, 657-663 (1991).
71. B. Van Houten, H. Gamper, S. R. Holbrook, J. E. Hearst and A. Sancar, Action mechanism of ABC excision nuclease on a DNA substrate containing a psoralen crosslink at a defined position. Proc. Natl. Acad. Sci. USA 83, 8077-8081 (1986).
72. M. Berardini, W. Mackay and E. L. Loechler, Evidence for a recombination-independent pathway for the repair of DNA interstrand cross-links based on a site-specific study with nitrogen mustard. Biochemistry 36, 3506-3513 (1997).
73. M. Berardini, P. L. Foster and E. L. Loechler, DNA polymerase II (polB) is involved in a new DNA repair pathway for DNA interstrand cross-links in Escherichia coli. J. Bacteriol. 181, 2878-2882 (1999).
74. K. M. Vasquez, J. M. Dagle, D. L. Weeks and P. M. Glazer, Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J. Biol. Chem. 276, 38536-38541 (2001).
75. P. A. Havre, E. J. Gunther, F. P. Gasparro and P. M. Glazer, Targeted mutagenesis of DNA using triple helix-forming oligonucleotides linked to psoralen. Proc. Natl. Acad. Sci. USA 90, 7879-7883 (1993).
76. J. G. Zendegui, K. M. Vasquez, J. H. Tinsley, D. J. Kessler and M. E. Hogan, In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res. 20, 307-314 (1992).
77. A. Majumdar, N. Puri, B. Cuenoud, F. Natt, P. Martin, A. Khorlin, N. Dyatkina, A. J. George and M. M. Seidman, Cell cycle modulation of gene targeting by a triple helix-forming oligonucleotide. J. Biol. Chem. 278, 11072-11077 (2003).
78. C. von Sonntag, The Chemical Basis of Radiation Biology. Taylor & Francis, London, 1987.
79. K. M. Vasquez, T. G. Wensel, M. E. Hogan and J. H. Wilson, High-affinity triple helix formation by synthetic oligonucleotides at a site within a selectable mammalian gene. Biochemistry 34, 7243-7251 (1995).
80. D. Averbeck and S. Averbeck, DNA photodamage, repair, gene induction and genotoxicity following exposures to 254 nm UV and 8-methoxypsoralen plus UVA in a eukaryotic cell system. Photochem. Photobiol. 68, 289-295 (1998).
81. W. A. Saffran, C. R. Cantor, E. D. Smith and M. Magdi, Psoralen damage-induced plasmid recombination in Saccharomyces cerevisiae: Dependence on RAD1 and RAD52. Mutat. Res. 274, 1-9 (1992).
82. J. M. Vos and P. C. Hanawalt, DNA interstrand cross-links promote chromosomal integration of a selected gene in human cells. Mol. Cell Biol. 9, 2897-2905 (1989).
83. J. D. Hall and K. Scherer, Repair of psoralen-treated DNA by genetic recombination in human cells infected with herpes simplex virus. Cancer Res. 41, 5033-5038 (1981).
84. N. Zhang, X. Lu, X. Zhang, C. A. Peterson and R. J. Legerski, hMutSβ is required for the recognition and uncoupling of psoralen interstrand cross-links in vitro. Mol. Cell Biol. 22, 2388-2397 (2002).
85. Q. Wu, L. A. Christensen, R. J. Legerski and K. M. Vasquez, Mismatch repair participates in an error-free processing of DNA interstrand crosslinks in human cells. EMBO Rept. 6, 551-557 (2005).
86. K. K. Khanna and S. P. Jackson, DNA double-strand breaks: Signaling, repair and the cancer connection. Nat. Genet. 27, 247-254 (2001).
87. D. C. van Gent, J. H. Hoeijmakers and R. Kanaar, Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2, 196-206 (2001).
88. G. A. Cromie, J. C. Connelly and D. R. Leach, Recombination at double-strand breaks and DNA ends: Conserved mechanisms from phage to humans. Mol. Cell. 8, 1163-1174 (2001).
89. J. E. Haber, Partners and pathways repairing a double-strand break. Trends Genet. 16, 259-264 (2000).
90. M. Takata, M. S. Sasaki, E. Sonoda, C. Morrison, M. Hashimoto, H. Utsumi, Y. Yamaguchi-Iwai, A. Shinohara and S. Takeda, Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 17, 5497-5508 (1998).
91. S. E. Lee, R. A. Mitchell, A. Cheng and E. A. Hendrickson, Evidence for DNA-PK-dependent and -independent DNA double-strand break repair pathways in mammalian cells as a function of the cell cycle. Mol. Cell Biol. 17, 1425-1433 (1997).
92. G. Damia, L. Imperatori, M. Stefanini and M. D'Incalci, Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer 66, 779-783 (1996).
93. I. Kuraoka, W. R. Kobertz, R. R. Ariza, M. Biggerstaff, J. M. Essigmann and R. D. Wood, Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J. Biol. Chem. 275, 26632-26636 (2000).
94. T. Bessho, A. Sancar, L. H. Thompson and M. P. Thelen, Reconstitution of human excision nuclease with recombinant XPF-ERCC1 complex. J. Biol. Chem. 272, 3833-3837 (1997).
95. A. M. Sijbers, W. L. de Laat, R. R. Ariza, M. Biggerstaff, Y. F. Wei, J. G. Moggs, K. C. Carter, B. K. Shell, E. Evans and R. D. Wood, Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86, 811-822 (1996).
96. M. van Duin, J. de Wit, H. Odijk, A. Westerveld, A. Yasui, H. M. Koken, J. H. Hoeijmakers and D. Bootsma, Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 44, 913-923 (1986).
97. L. Bardwell, A. J. Cooper and E. C. Friedberg, Stable and specific association between the yeast recombination and DNA repair proteins RAD1 and RADIO in vitro. Mol. Cell. Biol. 12, 3041-3049 (1992).
98. J. Fishman-Lobell and J. E. Haber, Removal of nonhomologous DNA ends in double-strand break recombination: The role of the yeast ultraviolet repair gene RAD1. Science 258, 480-484 (1992).
99. N. A. Asaad, Z. C. Zeng, J. Guan, J. Thacker and G. Iliakis, Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: Reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 19, 5788-5800 (2000).
100. I. U. De Silva, P. J. McHugh, P. H. Clingen and J. A. Hartley, Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 20, 7980-7990 (2000).
101. L. C. Erickson, G. Laurent, N. A. Sharkey and K. W. Kohn, DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 288, 727-729 (1980).
102. S. Huerta, D. M. Harris, A. Jazirehi, B. Bonavida, D. Elashoff, E. H. Livingston and D. Heber, Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int. J. Oncol. 22, 663-670 (2003).
103. B. K. Chang, R. Gutman and T. C. Chou, Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. Cancer Res. 47, 2247-2250 (1987).
104. Z. H. Siddik, Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279 (2003).
105. M. Bustin, Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19, 5237-5246 (1999).
106. J. O. Thomas and A. A. Travers, HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem. Sci. 26, 167-174 (2001).
107. R. Reeves, Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 277, 63-81 (2001).
108. M. Bustin, L. Trieschmann and Y. V. Postnikov, The HMG-14/-17 chromosomal protein family: Architectural elements that enhance transcription from chromatin templates. Semin. Cell Biol. 6, 247-255 (1995).
109. M. I. Mosevitsky, V. A. Novitskaya, M. G. Iogannsen and M. A. Zabezhinsky, Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur. J. Biochem. 185, 303-310 (1989).
110. S. Prasad and M. K. Thakur, Distribution of high mobility group proteins in different tissues of rats during aging. Biochem. Int. 20, 687-695 (1990).
111. L. G. Sheflin, N. W. Fucile and S. W. Spaulding, The specific interactions of HMG 1 and 2 with negatively supercoiled DNA are modulated by their acidic C-terminal domains and involve cysteine residues in their HMG 1/2 boxes. Biochemistry 32, 3238-3248 (1993).
112. M. Bustin and R. Reeves, High-mobility-group chromosomal proteins: Architectural components that facilitate chromatin function. Prog. Nucleic Acid Res. Mol. Biol. 54, 35-100 (1996).
113. B. Degryse and M. de Virgilio, The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 553, 11-17 (2003).
114. S. Calogero, F. Grassi, A. Aguzzi, T. Voigtlander, P. Ferrier, S. Ferrari and M. E. Bianchi, The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22, 276-280 (1999).
115. L. Ronfani, M. Ferraguti, L. Croci, C. E. Ovitt, H. R. Scholer, G. G. Consalez and M. E. Bianchi, Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 128, 1265-1273 (2001).
116. P. M. Pil and S. J. Lippard, Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237 (1992).
117. J. Lanuszewska and P. Widlak, High mobility group 1 and 2 proteins bind preferentially to DNA that contains bulky adducts induced by benzo[a]pyrene diol epoxide and N-acetoxy-acetylaminofluorene. Cancer Lett. 158, 17-25 (2000).
118. J. F. Wang, M. Bashir, B. N. Engelsberg, C. Witmer, H. Rozmiarek and P. C. Billings, High mobility group proteins 1 and 2 recognize chromium-damaged DNA. Carcinogenesis 18, 371-375 (1997).
119. E. A. Pasheva, I. G. Pashev and A. Favre, Preferential binding of high mobility group I protein to UV-damaged DNA. Role of the COOH-terminal domain. J. Biol. Chem. 273, 24730-24736 (1998).
120. M. E. Bianchi, M. Beltrame and G. Paonessa, Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243, 1056-1059 (1989).
121. L. Jayaraman, N. C. Moorthy, K. G. Murthy, J. L. Manley, M. Bustin and C. Prives, High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12, 462-472 (1998).
122. K. McKinney and C. Prives, Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell Biol. 22, 6797-6808 (2002).
123. Q. He, C. H. Liang and S. J. Lippard, Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc. Natl. Acad. Sci. USA 97, 5768-5772 (2000).
124. J. C. Huang, D. B. Zamble, J. T. Reardon, S. J. Lippard and A. Sancar, HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA 91, 10394-10398 (1994).
125. E. Y. Krynetski, N. F. Krynetskaia, M. E. Bianchi and W. E. Evans, A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res. 63, 100-106 (2003).